• Agora
  • Eioc Mededge
MedEdge MEA MedEdge_Logo_Dark

Public Relations, Top Health Magazine and Healthcare News GCC

  • Newsletters
  • Magazines
  • Subscribe
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
      • Healthcare Journals & Publishers
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Reading: New Study: Updated Hepatitis B vaccine more effective for people with HIV
Share
Notification
  • Agora
  • Eioc Mededge
MedEdge MEA
  • Magazines
  • Newsletters
  • Profiles
  • Subscribe
Search
  • Home
  • News
  • Opinion
  • Interviews
  • Featured
  • Cover Stories
  • Events
  • Health For all
    • Ageing Gracefully
    • Family Health Matters
    • Environment Health
    • Women and Child Health
    • Men’s Health
  • Resource Hub
    • Fresh Perspectives
    • Medical Tourism
    • Medical Education
    • Personnel
    • Research
    • Healthcare Campaigns
    • Health Tools Hub
    • Dubai Health Centers Directory | Services, Locations & Timings
Have an existing account? Sign In
MedEdge MEA > News > New Study: Updated Hepatitis B vaccine more effective for people with HIV
News

New Study: Updated Hepatitis B vaccine more effective for people with HIV

ME Desk
ME Desk
Published: December 16, 2024
Share
3 Min Read
HepB
SHARE

December 2024- A newer vaccine against Hepatitus B virus was superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

The study, reported on Dec. 1 in JAMA, showed that the hepatitis B vaccine with a cytosine phosphoguanine adjuvant, known as HepB-CpG, (trade name Heplisav-B) induced protective levels of antibodies in up to 99.4% of the subjects who received it. Such protection was seen in only 80.6% of subjects who received the hepatitis B vaccine with an aluminium hydroxide adjuvant, known as HepB-alum, (trade name Engerix-B).

“These results suggest a potential path forward for the large number of people living with HIV who can’t get protection from older hepatitis B vaccines,” said study corresponding author Dr. Kristen Marks, an associate professor of medicine at Weill Cornell Medicine and an infectious disease specialist at NewYork-Presbyterian/Weill Cornell Medical Center.

Hepatitis B virus is spread mostly by the transfer of body fluids during childbirth, sex, and needle-sharing during drug use. It can establish a chronic, often symptomless, liver infection that can progress to liver cirrhosis and/or liver cancer. The World Health Organization estimated in 2022 that more than 250 million people globally were living with chronic hepatitis B infection and that more than a million would die from it that year.

Also Read : 1 in 5 adults worldwide has a genital herpes infection- WHO

Prior research has found that Heplisav-B induces high rates of protective antibody responses in patients with diabetes or end-stage kidney disease who tend to respond poorly to traditional hepatitis B vaccines. In an earlier part of the current study, Dr. Marks and colleagues also found that Heplisav-B induced protective antibody responses in 100% of people with HIV who had otherwise never been vaccinated against hepatitis B.

The new analysis included three arms: the HepB-CpG vaccine in three doses, the HepB-alum vaccine in three doses, and the HepB-CpG vaccine in its standard regimen of two doses. Both of the Hep-CpG arms were superior to HepB-alum, with 99.4% (three-doses) and 93.1% (two doses) of people in those groups showing protective levels of vaccine-induced antibodies, compared with 80.6% of those in the HepB-alum group. The trial did not uncover new safety issues.

Share This Article
Facebook Whatsapp Whatsapp LinkedIn Copy Link
Share
Previous Article paracetamol Is repeated Paracetamol use putting seniors at risk of serious complications?
Next Article HPV Could HPV Self-Testing lead to better cervical cancer screening?

Recent Posts

  • From Skin Types to Chronic Conditions: Dr. Jawaher Al Naqbi | AIDA 2025
  • Merck to Host Investor Event Highlighting Advances in HIV Treatment and Prevention Pipeline
  • National University Hospital (Singapore) is First to Receive International Healthcare Sustainability Certification
  • Roche Announces Retirement of Key Executives
  • WHO Supports Health Response in Flood Affected Mokwa, Niger State
  • LifeSpin
  • Health ExpoIraq
  • Agora
  • Holistic Health Middle East
  • Holistic Health Middle East MedEdge
Two Point Five Logo white
  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: New Study: Updated Hepatitis B vaccine more effective for people with HIV
Share

Published by Two Point Five Media FZCO

  • About Us
  • Terms and Conditions
  • Privacy Policy
  • Submit Your Story
  • Contact Us
  • MediaKit
Reading: New Study: Updated Hepatitis B vaccine more effective for people with HIV
Share

Follow US on Social Media

Facebook Instagram Linkedin X-twitter Youtube Whatsapp

WhatsApp us

Logo of Medede mea
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?